Listen
Reason for request
Re-assessment of the actual benefit and the improvement in actual benefit, on the initiative of the Transparency Committee (in pursuance of Article R-163-21 of the Social Security Code).
-
Clinical Benefit
| Moderate |
The Committee considers that the AB of RASILEZ HCT is : - moderate in patients whose blood pressure is not adequately controlled by aliskiren used alone or in substitution therapy in patients whose blood pressure is adequately controlled by aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in RASILEZ HCT, |
| Insufficient |
- insufficient in hypertensive patients treated with a combination already containing an inhibitor of the renin-angiotensin-aldosterone system (CEI or ARB), including patients with diabetes or renal impairment, - insufficient in patients whose blood pressure is not adequately controlled on treatment containing hydrochlorothiazide used alone. |
